Company / Cash & Equivalents
Fulcrum Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$197.5M
FY2025
5-year range
$25.6M / $197.5M
FY2021-FY2025
Trend
+239.3%
vs FY2024
Sector context
#87 of 207
Health Care
What the data says
Cash & Equivalents changed +239% YoY in FY2025, a notable deviation from the 7-year average annual change of +42%.
Based on SEC 10-K filings.
$198M in FY2025 with a 5-year CAGR of +28.2%.
Improved from $26M to $198M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +77.9%
- 5-Year CAGR
- +28.2%
- 10-Year CAGR
- -
Sector benchmark
#87 of 207 in Health CareTop 42% of 207This company $197.5M Sector average $669.5M
▼
-70.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +28.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 239.3% year-over-year.
- Ranks #87 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $197.5M | +239.3% |
| FY2024 | $58.2M | +127.7% |
| FY2023 | $25.6M | -27.2% |
| FY2022 | $35.1M | -0.9% |
| FY2021 | $35.4M | -37.9% |
| FY2020 | $57.1M | -41.0% |
| FY2019 | $96.7M | +32.9% |
| FY2018 | $72.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026